ES2127286T3 - Factor tisular truncado y activador de fviia o fvii para la coagulacion de la sangre. - Google Patents
Factor tisular truncado y activador de fviia o fvii para la coagulacion de la sangre.Info
- Publication number
- ES2127286T3 ES2127286T3 ES93913844T ES93913844T ES2127286T3 ES 2127286 T3 ES2127286 T3 ES 2127286T3 ES 93913844 T ES93913844 T ES 93913844T ES 93913844 T ES93913844 T ES 93913844T ES 2127286 T3 ES2127286 T3 ES 2127286T3
- Authority
- ES
- Spain
- Prior art keywords
- fviia
- ttf
- activator
- factor
- viia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012190 activator Substances 0.000 title abstract 4
- 102000002262 Thromboplastin Human genes 0.000 title abstract 2
- 108010000499 Thromboplastin Proteins 0.000 title abstract 2
- 230000023555 blood coagulation Effects 0.000 title 1
- 229940012414 factor viia Drugs 0.000 abstract 4
- 230000000740 bleeding effect Effects 0.000 abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 229940012413 factor vii Drugs 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96447—Factor VII (3.4.21.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/04—Phospholipids, i.e. phosphoglycerides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE HA DESCUBIERTO QUE ES POSIBLE ADMINISTRAR FACTOR DE TEJIDO TRUNCADO, NO TENIENDO UNA ZONA TRANSMEMBRANA (TTF) EN COMBINACION CON EL FACTOR VIIA (FVIIA) O UN ACTIVADOR DEL FACTOR VII ENDOGENO, PARA TRATAR TRASTORNOS SANGRANTES TALES COMO LOS QUE SE PRODUCEN EN LA HEMOFILIA O CIRROSIS DEL HIGADO. EL TTF SE ADMINISTRA PARA OBTENER HASTA 10 (MU)G TTF/ML DE PLASMA. EL ACTIVADOR FVIIA O FVII SE ADMINISTRA PARA OBTENER NIVELES ENTRE 40 (MU)G VIIA/ML Y 700 (MU)G FVIIA/ML DE PLASMA. LAS DOSIS EFICACES DE AMBOS TTF Y ACTIVADOR VII DE VIIA/FACTOR SON SIGNIFICATIVA Y SORPRENDENTEMENTE INFERIORES A LA ADMINISTRACION DE CUALQUIERA DE ELLOS AISLADO PARA DETENER LA SANGRADURA. EJEMPLOS DEMUESTRAN LA SEGURIDAD Y EFICACIA EN PERROS NORMALES Y HEMOFILICOS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/882,202 US5374617A (en) | 1992-05-13 | 1992-05-13 | Treatment of bleeding with modified tissue factor in combination with FVIIa |
US08/021,615 US5504064A (en) | 1991-04-10 | 1993-02-19 | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2127286T3 true ES2127286T3 (es) | 1999-04-16 |
Family
ID=26694897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93913844T Expired - Lifetime ES2127286T3 (es) | 1992-05-13 | 1993-05-12 | Factor tisular truncado y activador de fviia o fvii para la coagulacion de la sangre. |
Country Status (10)
Country | Link |
---|---|
US (1) | US5504064A (es) |
EP (1) | EP0642352B1 (es) |
JP (1) | JP3663550B2 (es) |
AT (1) | ATE175876T1 (es) |
AU (1) | AU676168B2 (es) |
CA (1) | CA2134750C (es) |
DE (1) | DE69323195T2 (es) |
DK (1) | DK0642352T3 (es) |
ES (1) | ES2127286T3 (es) |
WO (1) | WO1993023074A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472850A (en) * | 1991-04-10 | 1995-12-05 | Oklahoma Medical Research Foundation | Quantitative clotting assay for activated factor VII |
US5374617A (en) * | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
DE4416180C2 (de) * | 1994-05-06 | 1997-08-14 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats |
US6017891A (en) * | 1994-05-06 | 2000-01-25 | Baxter Aktiengesellschaft | Stable preparation for the treatment of blood coagulation disorders |
DE4416166C2 (de) * | 1994-05-06 | 1997-11-20 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
DK0771216T3 (da) * | 1994-07-11 | 2001-02-05 | Scripps Research Inst | Fremgangsmåder og præparater til specifik koagulering af tumorvaskulatur |
DE69628659D1 (de) * | 1995-11-22 | 2003-07-17 | Oklahoma Med Res Found | Verfahren zur bestimmung von blutgerinnungsfaktoren viii und ix |
US6379975B1 (en) | 1996-11-27 | 2002-04-30 | T.A.C. Thrombosis And Coagulation Aktiebolag | Methods and reagents for determining protein S |
IL130908A0 (en) * | 1997-01-22 | 2001-01-28 | Univ Texas | Tissue-factor (tf) compositions for coagulation and tumor treatment |
ES2255157T3 (es) * | 1997-04-23 | 2006-06-16 | Instrumentation Laboratory S.P.A. | Reactivo de tiempo de protrombina basado en el factor tisular recombinante de conejo. |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6017882A (en) * | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
IL140700A0 (en) * | 1998-07-13 | 2002-02-10 | Univ Texas | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
JP2002532440A (ja) | 1998-12-18 | 2002-10-02 | デュポン ファーマシューティカルズ カンパニー | ビトロネクチン受容体拮抗剤薬剤 |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
EP1140864A2 (en) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
EP2319541A1 (en) * | 2000-02-11 | 2011-05-11 | Bayer HealthCare LLC | Factor VII or VIIA-like conjugates |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
AU2001288819A1 (en) | 2000-09-11 | 2002-03-26 | Genentech, Inc. | Amidine inhibitors of serine proteases |
US6855509B2 (en) | 2000-12-19 | 2005-02-15 | Instrumentation Laboratory Company | Protein S functional assay and kit therefor |
WO2003028840A2 (en) * | 2001-09-27 | 2003-04-10 | Board Of Regents, The University Of Texas System | Combined compositions and methods for tumor vasculature coagulation and treatment |
DE60238435D1 (de) * | 2001-10-26 | 2011-01-05 | Scripps Research Inst | Gezielte thrombose durch gewebefaktor polypeptiden |
AU2003221469A1 (en) * | 2002-04-30 | 2003-11-17 | Bayer Healthcare Llc | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
AU2003266931B2 (en) * | 2002-09-30 | 2010-01-21 | Bayer Healthcare Llc | FVII or FVIIa variants having increased clotting activity |
US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
EP2085470B1 (en) * | 2003-03-20 | 2012-05-16 | Bayer HealthCare LLC | FVII or FVIIa variants |
AU2004247799B2 (en) * | 2003-06-19 | 2009-12-03 | Bayer Healthcare Llc | Factor VII or VIIa Gla domain variants |
US8461115B2 (en) | 2006-03-16 | 2013-06-11 | Stellaris Pharmaceuticals Aps | Methods for local treatment with factor VII |
EP1939218A1 (en) | 2006-12-29 | 2008-07-02 | Thrombotargets Europe, S.L. | Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof |
WO2009097429A1 (en) * | 2008-01-29 | 2009-08-06 | Leon Wortham | A fast acting primary hemostatic agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456591A (en) * | 1981-06-25 | 1984-06-26 | Baxter Travenol Laboratories, Inc. | Therapeutic method for activating factor VII |
US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
EP0225160B1 (en) * | 1985-11-26 | 1991-08-21 | Novo Nordisk A/S | Compositions and methods for the treatment of bleeding disorders |
IE81149B1 (en) * | 1987-02-12 | 2000-05-03 | Genentech Inc | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
WO1988009817A1 (en) * | 1987-06-12 | 1988-12-15 | Mount Sinai School Of Medicine Of The City Univers | Cloning and expression of human tissue factor |
DE3728491A1 (de) * | 1987-08-26 | 1989-03-09 | Heumann Pharma Gmbh & Co | Dihydropyridazinon-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5298599A (en) * | 1988-12-30 | 1994-03-29 | Oklahoma Medical Research Foundation | Expression and purification of recombinant soluble tissue factor |
US5472850A (en) * | 1991-04-10 | 1995-12-05 | Oklahoma Medical Research Foundation | Quantitative clotting assay for activated factor VII |
US5346991A (en) * | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
-
1993
- 1993-02-19 US US08/021,615 patent/US5504064A/en not_active Expired - Lifetime
- 1993-05-12 ES ES93913844T patent/ES2127286T3/es not_active Expired - Lifetime
- 1993-05-12 WO PCT/US1993/004493 patent/WO1993023074A1/en active IP Right Grant
- 1993-05-12 AT AT93913844T patent/ATE175876T1/de not_active IP Right Cessation
- 1993-05-12 JP JP50371594A patent/JP3663550B2/ja not_active Expired - Fee Related
- 1993-05-12 DK DK93913844T patent/DK0642352T3/da active
- 1993-05-12 EP EP93913844A patent/EP0642352B1/en not_active Expired - Lifetime
- 1993-05-12 CA CA002134750A patent/CA2134750C/en not_active Expired - Fee Related
- 1993-05-12 AU AU43729/93A patent/AU676168B2/en not_active Ceased
- 1993-05-12 DE DE69323195T patent/DE69323195T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH07508029A (ja) | 1995-09-07 |
DK0642352T3 (da) | 1999-09-13 |
AU4372993A (en) | 1993-12-13 |
WO1993023074A1 (en) | 1993-11-25 |
US5504064A (en) | 1996-04-02 |
DE69323195T2 (de) | 1999-10-14 |
EP0642352A1 (en) | 1995-03-15 |
AU676168B2 (en) | 1997-03-06 |
JP3663550B2 (ja) | 2005-06-22 |
CA2134750A1 (en) | 1993-11-25 |
CA2134750C (en) | 2008-01-15 |
DE69323195D1 (de) | 1999-03-04 |
ATE175876T1 (de) | 1999-02-15 |
EP0642352B1 (en) | 1999-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2127286T3 (es) | Factor tisular truncado y activador de fviia o fvii para la coagulacion de la sangre. | |
ES2167592T3 (es) | Preparaciones medicamentosas que contienen un enantiomero de bromuro de ipratropio con duracion de la accion prolongada. | |
ES2171469T3 (es) | Composicion administrada por via nasal y preparacion que la contiene. | |
DE69333775D1 (de) | Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten | |
Drayer et al. | Disseminated intravascular coagulation and head trauma: two case studies | |
DE69233398D1 (de) | Modifizierter faktor-vii | |
GR3002487T3 (en) | Medicament with anti-tumoral action containing hexadecylphosphocholine | |
DE69527966D1 (de) | Pharmazeutische zubereitung für die subkutane, intramuskuläre oder intradermale verabreichung von faktor viii | |
ES2048782T3 (es) | Un cuerno usado en un instrumento ultrasonico de intervencion quirurgica. | |
SV1995000088A (es) | Estructura absorbente elastomerica | |
DE69327432T2 (de) | Heilmittel für wunden und hämorrhoiden | |
US4721618A (en) | Method for controlling bleeding | |
ES2062011T3 (es) | Derivado de ciclohexano. | |
CO5160272A1 (es) | Combinacion de cerivastatina y fibratos | |
US4610880A (en) | Composition for controlling hemophilia in mammals | |
Aledort | Recombinant factor VIIa is a pan-hemostatic agent? | |
ES2039489T3 (es) | La utilizacion del compuesto alquilidenditio-bis-(substituidos)-fenoles sustituidos. | |
ES2059588T3 (es) | Factor xiii para la prevencion de una hemorragia intraventricular. | |
UY24063A1 (es) | Empleo de concentrados con contenido de factor von willebrand (vwf) como terapia de combinacion en la terapia con antitromboticos y fibrinoliticos | |
ES2039433T3 (es) | Una formulacion farmaceutica. | |
ATE428440T1 (de) | Thrombingenerierfähige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel | |
US4536392A (en) | Method for controlling hemophilia in mammals | |
ES2165855T3 (es) | Agente de normalizacion de la coagulacion sanguinea que contiene tcf-ii como ingrediente activo. | |
Corrigan Jr | Oral bleeding in hemophilia: treatment with epsilon aminocaproic acid and replacement therapy | |
ES2182504T3 (es) | Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 642352 Country of ref document: ES |